224 related articles for article (PubMed ID: 25411080)
1. Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Hoefert S; Hoefert CS; Albert M; Munz A; Grimm M; Northoff H; Reinert S; Alexander D
Clin Oral Investig; 2015 Jul; 19(6):1307-18. PubMed ID: 25411080
[TBL] [Abstract][Full Text] [Related]
2. Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Hoefert S; Sade Hoefert C; Munz A; Northoff H; Yuan A; Reichenmiller K; Reinert S; Grimm M
Clin Oral Investig; 2016 Jun; 20(5):1043-54. PubMed ID: 26349768
[TBL] [Abstract][Full Text] [Related]
3. Effect of bisphosphonates on macrophagic THP-1 cell survival in bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Hoefert S; Sade Hoefert C; Munz A; Schmitz I; Grimm M; Yuan A; Northoff H; Reinert S; Alexander D
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Mar; 121(3):222-32. PubMed ID: 26725718
[TBL] [Abstract][Full Text] [Related]
4. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Amigues C; Fresse A; Roux CH; Gauthier S; Vieillard MH; Drici MD; Breuil V;
Joint Bone Spine; 2023 Dec; 90(6):105599. PubMed ID: 37271278
[TBL] [Abstract][Full Text] [Related]
5. Alteration of macrophage viability, differentiation, and function by bisphosphonates.
Patntirapong S; Poolgesorn M
Oral Dis; 2018 Oct; 24(7):1294-1302. PubMed ID: 29869362
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.
Koch FP; Merkel C; Al-Nawas B; Smeets R; Ziebart T; Walter C; Wagner W
J Craniomaxillofac Surg; 2011 Dec; 39(8):562-9. PubMed ID: 21030265
[TBL] [Abstract][Full Text] [Related]
7. Further development of the MRONJ minipig large animal model.
Otto S; Pautke C; Martin Jurado O; Nehrbass D; Stoddart MJ; Ehrenfeld M; Zeiter S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1503-1514. PubMed ID: 28803745
[TBL] [Abstract][Full Text] [Related]
8. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
Otto S; Pautke C; Opelz C; Westphal I; Drosse I; Schwager J; Bauss F; Ehrenfeld M; Schieker M
J Oral Maxillofac Surg; 2010 Nov; 68(11):2837-45. PubMed ID: 20971371
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
11. Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).
Endo Y; Kumamoto H; Nakamura M; Sugawara S; Takano-Yamamoto T; Sasaki K; Takahashi T
Biol Pharm Bull; 2017; 40(6):739-750. PubMed ID: 28566618
[TBL] [Abstract][Full Text] [Related]
12. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis.
Aoki K; Matsunaga S; Ito S; Shibahara T; Nomura T; Matsuzaki H; Abe S; Yamaguchi A
J Bone Miner Metab; 2021 Sep; 39(5):737-747. PubMed ID: 33830351
[TBL] [Abstract][Full Text] [Related]
13. Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.
Elsayed R; Abraham P; Awad ME; Kurago Z; Baladhandayutham B; Whitford GM; Pashley DH; McKenna CE; Elsalanty ME
Bone; 2018 May; 110():141-149. PubMed ID: 29408511
[TBL] [Abstract][Full Text] [Related]
14. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F
Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
[TBL] [Abstract][Full Text] [Related]
15. Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.
Janovszky Á; Szabó A; Varga R; Garab D; Boros M; Mester C; Beretka N; Zombori T; Wiesmann HP; Bernhardt R; Ocsovszki I; Balázs P; Piffkó J
Clin Oral Investig; 2015 Jul; 19(6):1279-88. PubMed ID: 25352470
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate and pamidronate depress neutrophil functions and survival in mice.
Kuiper JW; Forster C; Sun C; Peel S; Glogauer M
Br J Pharmacol; 2012 Jan; 165(2):532-9. PubMed ID: 21745192
[TBL] [Abstract][Full Text] [Related]
17. The effects of bisphosphonate on the remodeling of different irregular bones in mice.
Su J; Feng M; Han W; Zhao H
J Oral Pathol Med; 2015 Sep; 44(8):638-48. PubMed ID: 25370709
[TBL] [Abstract][Full Text] [Related]
18. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
19. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
Yuan A; Munz A; Reinert S; Hoefert S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
[TBL] [Abstract][Full Text] [Related]
20. The effects of chronic zoledronate usage on the jaw and long bones evaluated using RANKL and osteoprotegerin levels in an animal model.
Çankaya M; Cizmeci Şenel F; Kadioglu Duman M; Muci E; Dayisoylu EH; Balaban F
Int J Oral Maxillofac Surg; 2013 Sep; 42(9):1134-9. PubMed ID: 23522850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
